L oral on the go

Author: t | 2025-04-23

The key to Oral Exam prep! L Oral is the best supplementary programme on the market to help prepare for the Oral exam, both at ordinary and higher level. With up-to-date content that reflects current trends as well as covering all aspects of the exam. L Oral eBook Digital here!

Oral hygiene on the go

B, Brambilla P. The Role and the Effect of Magnesium in Mental Disorders: A Systematic Review. Nutrients. 2020;12(6):1661. Published 2020 Jun 3. doi:10.3390/nu12061661 Barragán-Rodríguez L, Rodríguez-Morán M, Guerrero-Romero F. Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: a randomized, equivalent trial. Magnes Res. 2008;21(4):218-223. Guerrero-Romero F, Tamez-Perez HE, González-González G, et al. Oral magnesium supplementation improves sensitivity in non-diabetic subjects with resistance. A double-blind placebo-controlled randomized trial. Diabetes Metab. 2004;30(3):253-258. doi:10.1016/s1262-3636(07)70116-7 Takaya J, Higashino H, Kobayashi Y. Intracellular magnesium and resistance. Magnes Res. 2004;17(2):126-136. Schnack C, Bauer I, Pregant P, Hopmeier P, Schernthaner G. Hypomagnesaemia in type 2 diabetes mellitus is not corrected by improvement of long-term metabolic control. Diabetologia. 1992;35(1):77-79. doi:10.1007/BF00400855 Rodríguez-Morán M, Guerrero-Romero F. Oral magnesium supplementation improves sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care. 2003;26(4):1147-1152. doi:10.2337/diacare.26.4.1147 Askari M, Mozaffari H, Jafari A, Ghanbari M, Darooghegi Mofrad M. The effects of magnesium supplementation on obesity measures in adults: a systematic review and dose-response meta-analysis of randomized controlled trials [published online ahead of print, 2020 Jul 11]. Crit Rev Food Sci Nutr. 2020;1-17. doi:10.1080/10408398.2020.1790498 Asemi Z, Karamali M, Jamilian M, et al. Magnesium supplementation affects metabolic status and pregnancy outcomes in gestational diabetes: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2015;102(1):222-229. doi:10.3945/ajcn.114.098616 Zhang Y, Xun P, Wang R, Mao L, He K. Can Magnesium Enhance Exercise Performance?. Nutrients. 2017;9(9):946. Published 2017 Aug 28. doi:10.3390/nu9090946 Córdova A, Mielgo-Ayuso

Oral Foam On-the-go - blue m oral care

Chen KH, Liao KH, Liou ML. Subgingival microbiota in individuals with severe chronic periodontitis. J Microbiol Immunol Infect. 2018;51(2):226–34.Article PubMed Google Scholar Barros SP, Fahimipour F, Tarran R, Kim S, Scarel-Caminaga RM, Justice A, et al. Epigenetic reprogramming in periodontal disease: Dynamic crosstalk with potential impact in oncogenesis. Periodontol 2000. 2020;82(1):157–72.Article PubMed Google Scholar Caton JG, Armitage G, Berglundh T, Chapple ILC, Jepsen S, Kornman KS, et al. A new classification scheme for periodontal and peri-implant diseases and conditions - Introduction and key changes from the 1999 classification. J Periodontol. 2018;89(Suppl 1):S1-s8.PubMed Google Scholar Wilson M. Susceptibility of oral bacterial biofilms to antimicrobial agents. J Med Microbiol. 1996;44(2):79–87.Article CAS PubMed Google Scholar Pham TAV, Tran TTP, Luong NTM. Antimicrobial Effect of Platelet-Rich Plasma against Porphyromonas gingivalis. Int J Dent. 2019;2019:7329103.Article PubMed PubMed Central Google Scholar Nibali L, Koidou V, Salomone S, Hamborg T, Allaker R, Ezra R, et al. Minimally invasive non-surgical vs. surgical approach for periodontal intrabony defects: a randomised controlled trial. Trials. 2019;20(1):461.Article CAS PubMed PubMed Central Google Scholar Nibali L, Pometti D, Chen TT, Tu YK. Minimally invasive non-surgical approach for the treatment of periodontal intrabony defects: a retrospective analysis. J Clin Periodontol. 2015;42(9):853–9.Article PubMed Google Scholar Graziani F, Karapetsa D, Alonso B, Herrera D. Nonsurgical and surgical treatment of periodontitis: how many options for one disease? Periodontol 2000. 2017;75(1):152–88.Article PubMed Google Scholar Chatzopoulos GS, Koidou VP, Tsalikis L. Local drug delivery in the treatment of furcation defects in periodontitis: a systematic review. Clin Oral Investig. 2023;27(3):955–70.Article PubMed PubMed Central Google Scholar Gomes EWB, Casarin M, Martins TM, da Silva AF. Local delivery therapies as adjuvants to non-surgical periodontal treatment of periodontitis grade C: a systematic review. Clin Oral Investig. 2020;24(12):4213–24.Article PubMed Google Scholar Arduino PG, Cabras M, Lodi G, Petti S. Herpes simplex virus type 1

On-The-Go Oral Care Products - TePe Oral Health

Looks like a tablet. This is the empty shell from the tablet after the medicine has been absorbed by your body.•If you take too much XELJANZ/XELJANZ XR/XELJANZ Oral Solution, call your healthcare provider or go to the nearest hospital emergency room right away.•For the treatment of psoriatic arthritis, take XELJANZ/XELJANZ XR in combination with methotrexate, sulfasalazine or leflunomide as instructed by your healthcare provider.•XELJANZ XR should not be used instead of XELJANZ Oral Solution.What are the possible side effects of XELJANZ/XELJANZ XR/XELJANZ Oral Solution?XELJANZ/XELJANZ XR/XELJANZ Oral Solution may cause serious side effects, including:•See "What is the most important information I should know about XELJANZ/XELJANZ XR/XELJANZ Oral Solution?"•Hepatitis B or C activation infection in people who carry the virus in their blood. If you are a carrier of the hepatitis B or C virus (viruses that affect the liver), the virus may become active while you use XELJANZ/XELJANZ XR/XELJANZ Oral Solution. Your healthcare provider may do blood tests before you start treatment with XELJANZ/XELJANZ XR/XELJANZ Oral Solution and while you are taking XELJANZ/XELJANZ XR/XELJANZ Oral Solution. Tell your healthcare provider if you have any of the following symptoms of a possible hepatitis B or C infection: ofeel very tiredolittle or no appetiteoclay-colored bowel movementsochillsomuscle achesoskin rash oskin or eyes look yellowovomitingofeversostomach discomfortodark urineCommon side effects of XELJANZ/XELJANZ XR in people with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis include: •upper respiratory tract infections (common cold, sinus infections)•headache•diarrhea•nasal congestion, sore throat, and runny nose (nasopharyngitis)•high blood pressure (hypertension)•acneCommon side effects of XELJANZ/XELJANZ XR in people with ulcerative colitis include: •nasal congestion, sore throat, and runny nose (nasopharyngitis)•increased cholesterol levels•headache•upper respiratory tract infections (common cold, sinus infections)•increased muscle enzyme levels•rash•acne•diarrhea•shingles (herpes zoster)Common side effects of XELJANZ/XELJANZ Oral Solution in people with polyarticular course juvenile arthritis include:•upper respiratory tract infections (common cold, sinus infections)•nasal congestion, sore throat, and runny nose (nasopharyngitis)•headache•fever•nausea•vomiting•acneTell your healthcare provider if you have any side effect that bothers you or that does not go away.These are not all the possible side effects of XELJANZ/XELJANZ XR/XELJANZ Oral Solution. For more information, ask your healthcare provider or pharmacist.Call your doctor for medical. The key to Oral Exam prep! L Oral is the best supplementary programme on the market to help prepare for the Oral exam, both at ordinary and higher level. With up-to-date content that reflects current trends as well as covering all aspects of the exam. L Oral eBook Digital here!

Oral hygiene on the go - Nature

Dentition of Class II division I children, and the effect of gender on the appliance outcomes. It would be a point of interest to conduct further studies to evaluate the effect of myofunctional appliances in children with TMJ disorders as this would directly affect the muscles’ actions and, accordingly, the appliance outcomes. Author ContributionsY.E. and A.A.E.-H. and H.A.I.; Conceptualization, Y.E, H.A.I.; Methodology, Y.E., A.A.E.-H., H.A.I., L.M.E.H.; Investigation. Y.E., and L.M.E.H.; Writing original draft, review and editing, visualization, A.A.E.-H. and H.A.I. Supervised and critically revised the manuscript. All authors have read and agreed to the published version of the manuscript.FundingThis research received no external funding.Conflicts of InterestThe authors declare no conflicts of interest.ReferencesMoyers, R.E.; Riolo, M.L.; Guire, K.E.; Wainright, R.L.; Bookstein, F.L. Differential diagnosis of Class II malocclusions: Part 1. Facial types associated with Class II malocclusions. Am. J. Orthod. 1980, 78, 477–494. [Google Scholar] [CrossRef]Isola, G.; Anastasi, G.P.; Matarese, G.; Williams, R.C.; Cutroneo, G.; Bracco, P.; Piancino, M.G. Functional and molecular outcomes of the human masticatory muscles. Oral Dis. 2018, 24, 1428–1441. [Google Scholar] [CrossRef] [PubMed]Isola, G.; Perillo, L.; Migliorati, M.; Matarese, M.; Dalessandri, D.; Grassia, V.; Alibrandi, A.; Matarese, G. The impact of temporomandibular joint arthritis on functional disability and global health in patients with juvenile idiopathic arthritis. Eur. J. Orthod. 2019, 41, 117–124. [Google Scholar] [CrossRef] [PubMed]Ivorra-Carbonell, L.; Montiel-Company, J.M.; Almerich-Silla, J.M.; Paredes-Gallardo, V.; Bellot-Arcís, C. Impact of functional mandibular advancement appliances on the temporomandibular joint—A systematic review. Med. Oral Patol. Oral Cir. Bucal. 2016, 21, e565–e572. [Google Scholar] [CrossRef] [PubMed] [Green Version]Jena, A.K.; Duggal, R.; Parkash, H. Skeletal and dentoalveolar effects of Twin-block and bionator appliances in the treatment of Class II malocclusion: A comparative study. Am. J. Orthod. Dentofac. Orthop. 2006, 130, 594–602. [Google Scholar] [CrossRef] [PubMed]Clark, W.J. Twin Block Functional Therapy; Mosby-Wolfe: London, UK, 1995;

On-the-Go Oral Care Products

Home / Products / Compact Travel Oral Care Bundle: Portable USB Rechargeable Collapsible Water Flosser and Pursonic Portable Electric Toothbrush " data-image-zoom="23451559329815"> $56.98 | / Quantity: Upgrade your oral hygiene routine on the go with our Travel Oral Care Bundle, featuring the Portable USB Rechargeable Collapsible Water Flosser and the Pursonic Portable Sonic Toothbrush. Whether you're traveling for business or leisure, these compact and efficient tools ensure you maintain a healthy and vibrant smile wherever you are.Key Features:Portable USB Rechargeable Collapsible Water Flosser:Collapsible Design: Compact and collapsible for maximum portability.Cordless Convenience: Enjoy hassle-free cordless usage anywhere.USB Rechargeable: Charge it using your laptop, power bank, or any USB-compatible device.Three Jet Settings: Choose between gentle, standard, or powerful modes.Up to 1200 Pulses Per Minute: Effectively remove debris and plaque for thorough cleaning.Versatile Use: Ideal for home, office, or travel.Pursonic Portable Sonic Toothbrush:Compact Design: Pocket-sized and stylish for on-the-go use.Battery Operated: Battery included for immediate use.Three Brush Heads Included: Enjoy a 3-month supply of brush heads.22,000 Strokes Per Minute: Removes plaque along the gum line and deep between teeth.High Quality: DuPont bristles promote naturally whiter teeth.Sonic Toothbrush: Promotes efficient and gentle cleaning with sleek design.Convenience and Efficiency Combined:Experience the convenience of efficient oral care with our Travel Oral Care Bundle. Keep your smile healthy and vibrant wherever your travels take you. Invest in your oral health today!

On-The-Go Oral Care Products - TePe Oral Health Care, Inc.

In a patient with multiple myeloma. Conn Med. 2004 Feb. 68(2):71-2. [QxMD MEDLINE Link]. Larner AJ. Pseudohyperphosphatemia. Clin Biochem. 1995 Aug. 28(4):391-3. [QxMD MEDLINE Link]. Leehey DJ, Daugirdas JT, Ing TS, Reid RW. Spurious hyperphosphatemia due to hyperlipidemia. Arch Intern Med. 1985 Apr. 145(4):743-4. [QxMD MEDLINE Link]. Beloosesky Y, Grinblat J, Weiss A, et al. Electrolyte disorders following oral sodium phosphate administration for bowel cleansing in elderly patients. Arch Intern Med. 2003 Apr 14. 163(7):803-8. [QxMD MEDLINE Link]. Gumurdulu Y, Serin E, Ozer B, Gokcel A, Boyacioglu S. Age as a predictor of hyperphosphatemia after oral phosphosoda administration for colon preparation. J Gastroenterol Hepatol. 2004. 19:68-72. [QxMD MEDLINE Link]. Markowitz GS, Stokes MB, Radhakrishnan J, D'Agati VD. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J Am Soc Nephrol. 2005. 16:3389-3396. [QxMD MEDLINE Link]. Markowitz GS, Nasr SH, Klein P, Anderson H, Stack JI, Alterman L, et al. Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing. Hum Pathol. 2004. 35:675-684. [QxMD MEDLINE Link]. Yoo KD, Kang S, Choi Y, Yang SH, Heo NJ, Chin HJ, et al. Sex, Age, and the Association of Serum Phosphorus With All-Cause Mortality in Adults With Normal Kidney Function. Am J Kidney Dis. 2015 Sep 2. [QxMD MEDLINE Link]. Connolly GM, Cunningham R, McNamee PT, Young IS, Maxwell AP. Elevated serum phosphate predicts mortality in renal transplant recipients. Transplantation. 2009. 87:1041-1044. [QxMD MEDLINE Link]. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008. 52:519-530. [QxMD MEDLINE Link]. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney International. 2008. 74:148-157. [QxMD MEDLINE Link]. [Full Text]. [Guideline] Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int. 2017 Jul.

Delivering better oral health on the go

Chronic Periodontitis - A Clinical Study. J Int Oral Health. 2013;5(5):79–84.PubMed PubMed Central Google Scholar Nardi GM, Cesarano F, Papa G, Chiavistelli L, Ardan R, Jedlinski M, et al. Evaluation of Salivary Matrix Metalloproteinase (MMP-8) in Periodontal Patients Undergoing Non-Surgical Periodontal Therapy and Mouthwash Based on Ozonated Olive Oil: A Randomized Clinical Trial. Int J Environ Res Public Health. 2020;17(18):6619.Article CAS PubMed PubMed Central Google Scholar Ranjith A, Niranjana JM, Baiju KV. Adjunctive benefit of ozonized water irrigation with mechanical debridement in the management of Stage III periodontitis: A randomized controlled clinical and biochemical study. Int J Dent Hyg. 2022;20(2):364–70.Article PubMed Google Scholar Rapone B, Ferrara E, Santacroce L, Topi S, Gnoni A, Dipalma G, et al. The Gaseous Ozone Therapy as a Promising Antiseptic Adjuvant of Periodontal Treatment: A Randomized Controlled Clinical Trial. Int J Environ Res Public Health. 2022;19(2):985.Article PubMed PubMed Central Google Scholar Seydanur Dengizek E, Serkan D, Abubekir E, Aysun Bay K, Onder O, Arife C. Evaluating clinical and laboratory effects of ozone in non-surgical periodontal treatment: a randomized controlled trial. J Appl Oral Sci. 2019;27: e20180108.Article CAS PubMed PubMed Central Google Scholar Tasdemir Z, Oskaybas MN, Alkan AB, Cakmak O. The effects of ozone therapy on periodontal therapy: A randomized placebo-controlled clinical trial. Oral Dis. 2019;25(4):1195–202.Article PubMed Google Scholar Uraz A, Karaduman B, Isler S, Gönen S, Çetiner D. Ozone application as adjunctive therapy in chronic periodontitis: Clinical, microbiological and biochemical aspects. J Dent Sci. 2019;14(1):27–37.Article PubMed Google Scholar Yılmaz S, Algan S, Gursoy H, Noyan U, Kuru BE, Kadir T. Evaluation of the clinical and antimicrobial effects of the Er:YAG laser or topical gaseous ozone as adjuncts to initial periodontal therapy. Photomed Laser Surg. 2013;31(6):293–8.Article PubMed Google Scholar Al-Omiri MK, Alhijawi M, AlZarea BK, Abul Hassan RS, Lynch E. Ozone treatment of recurrent aphthous. The key to Oral Exam prep! L Oral is the best supplementary programme on the market to help prepare for the Oral exam, both at ordinary and higher level. With up-to-date content that reflects current trends as well as covering all aspects of the exam. L Oral eBook Digital here!

ORAL HEALTH ON-THE-GO - Google Sites

Glycopyrronium).Each capsule of glycopyrrolate/indacaterol oral inhalation powder (Utibron Neohaler) contains 15.6 mcg of glycopyrrolate and 27.5 mcg of indacaterol. Actual amount of drug delivered to the lungs depends on factors such as the patient’s inspiratory flow rate and inspiratory time. Under standardized in vitro testing at a fixed flow rate of 90 L/minute for 1.3 seconds, the Neohaler device delivered 12.8 mcg of glycopyrrolate (equivalent to 12.5 mcg of glycopyrronium) and 20.8 mcg of indacaterol from the capsule containing 15.6 mcg of glycopyrrolate and 27.5 mcg of indacaterol.Oral Inhalation SolutionAdminister glycopyrrolate oral inhalation solution via nebulization using a special oral inhalation device (Magnair nebulizer system). Administer the inhalation solution twice daily at the same time each day.Glycopyrrolate solution for oral inhalation should not be taken orally (i.e., swallowed) and should not be injected.Assemble Magnair nebulizer system according to manufacturer's instructions for use and ensure it is working properly.Immediately prior to use, open the foil pouch; remove and separate the 2 single-dose vials; return one vial to the foil pouch and store in the nebulizer carrying bag. Insert vial to be used into bottom of medication cap until it clicks. Place medication cap with vial on top of handset body (with aerosol head already inserted) and turn in a clockwise direction until a click is heard; avoid touching the part of handset body that pierces the vial. Line up notch in medication cap with blue line on handset body.To administer the dose, insert mouthpiece, press controller on/off button, and breathe normally through the mouthpiece. Avoid tilting handset, loosening or removing medication cap, or unclasping the handset body until treatment is complete. At the end of treatment (2–3 minutes), a beep will sound and controller will shut off automatically.Follow manufacturer's instructions for cleaning handset after each treatment.Each single-dose vial of glycopyrrolate oral inhalation solution (Lonhala Magnair) contains 25 mcg of glycopyrrolate in 1 mL of solution. Actual amount of drug delivered to the lungs depends on patient factors. Under standardized in vitro testing, the Magnair device delivered approximately 14.2 mcg of glycopyrrolate (equivalent to 11.4 mcg of glycopyrronium) from the mouthpiece.Oral Inhalation AerosolAdminister glycopyrrolate/formoterol fixed combination using a special oral inhalation device (Aerosphere) that delivers a metered-dose spray. Administer the oral inhalation aerosol as 2 inhalations twice daily (morning and evening).Before first use, ensure that inhaler device (Bevespi Aerosphere) is at room temperature. Remove inhaler from foil pouch.Shake well before each inhalation. Prime inhaler before first use. Remove cap from mouthpiece. Hold inhaler in upright position away from face. To release spray from the mouthpiece, press down firmly on center of dose indicator until canister stops moving in actuator; soft click may be heard. Repeat 3 more times, shaking well before each

Oral Surgery, Oral Medicine, Oral Pathology and Oral

TherapyW Sound Articulation TherapyPhonological disorders are more complex, as they are patterns in a child’s speech used to simplify speech sound production. An example of this is when a child deletes the last sound off of a word. They might say /ca/ for /cat/ or /si/ for /sit/. The majority of children with highly unintelligible speech present with a phonological disorder, as their speech is characterized by repeating patterns of incorrect productions.Children have a phonological disorder if they:are able to make the sounds correctly, but they may use it in the wrong position in a word, or in the wrong word, e.g. a child may use the d sound instead of the g sound, and so they say “doe” instead of “go”;make mistakes with the particular sounds in words, e.g. they can say k in “kite” but with certain words, will leave it out e.g. “lie” instead of “like.” The types of disorders in phonological processes chart:Phonological ProcessDescriptionExampleFrontingreplacement of a sound typically produced in the back of the oral cavity with a front sound “tar” for “car,” “tandy” for “candy”Backingreplacement of a sound typically produced in the front of the oral cavity with a back sound “gog” for “dog”Final Consonant Deletionomission/deleting of final consonant“cu” for “cup”Cluster Reductionsimplification of a cluster (two letter sound) into single sound“poon” for “spoon”Weak syllable deletiondeletion of weak syllable in word“tefone” for “telephone”Glidingsound /r/ and /l/ replaced by /w/ and “j”“wadder” for “ladder”Stoppingreplacement of sounds“too” for “shoe”Reduplicationrepetition of syllables“wawa” for “water”Prevocalic Voicingreplacement of voiceless consonant with a voiced consonant“vone” for “phone”Initial Consonant Deletiondeletion of initial consonant“ose” for “nose”Epenthesisaddition of “uh” sound in between two consonants“puh-lane” for “plane”It’s important to know that children’s speech goes through normal articulation and phonological errors. By 2-years-of-age, a child’s speech should be 50% intelligible to an unfamiliar listener, by 3-years-of-age 75%. The key to Oral Exam prep! L Oral is the best supplementary programme on the market to help prepare for the Oral exam, both at ordinary and higher level. With up-to-date content that reflects current trends as well as covering all aspects of the exam. L Oral eBook Digital here!

Best On-the-Go Oral Hygiene Tools - ryandental.com

I Int J Periodontics Restorative Dent. 1989;9:84–105 Cited Here 39. Seibert JS, Louis JV. Soft tissue ridge augmentation utilizing a combination onlay-interpositional graft procedure: A case report Int J Periodontics Restorative Dent. 1996;16:310–21 Cited Here 40. Sullivan HC, Atkins JH. The role of free gingival grafts in periodontal therapy Dent Clin North Am. 1969;13:133–48 Cited Here 41. Langer B, Sullivan DY. Osseointegration: Its impact on the interrelationship of periodontics and restorative dentistry. II Int J Periodontics Restorative Dent. 1989;9:165–84 Cited Here 42. Sclar AG. Strategies for management of single-tooth extraction sites in aesthetic implant therapy J Oral Maxillofac Surg. 2004;62(Suppl 2):90–105 Cited Here 43. Landi L, Sabatucci D. Plastic surgery at the time of membrane removal around mandibular endosseous implants: A modified technique for implant uncovering Int J Periodontics Restorative Dent. 2001;21:280–7 Cited Here 44. Sohn JY, Park JC, Cho KS, Kim CS. Simultaneous placement of an interpositional free gingival graft with nonsubmerged implant placement J Periodontal Implant Sci. 2014;44:94–99 Cited Here 45. Caneva M, Botticelli D, Vigano P, Morelli F, Rea M, Lang NP. Connective tissue grafts in conjunction with implants installed immediately into extraction sockets. An experimental study in dogs Clin Oral Implants Res. 2013;24:50–6 Cited Here 46. Allen EP, Miller PD Jr. Coronal positioning of existing gingiva: Short term results in the treatment of shallow marginal tissue recession J Periodontol. 1989;60:316–319 Cited Here 47. Covani U, Marconcini S, Galassini G, Cornelini R, Santini S, Barone A. Connective tissue graft used as a biologic barrier to cover an immediate implant J Periodontol. 2007;78:1644–9 Cited Here 48. Wiesner G, Esposito M, Worthington H, Schlee M. Connective tissue grafts for thickening peri-implant tissues at implant placement. One-year results from an explanatory split-mouth randomised controlled clinical trial Eur J Oral Implantol. 2010;3:27–35 Cited Here 49. Belser UC, Schmid B, Higginbottom F, Buser D. Outcome analysis of implant restorations located in the anterior maxilla: A review of the recent literature Int J Oral Maxillofac Implants. 2004;19(Suppl):30–42 Cited Here 50. Cosyn J, Raes M, Packet M, Cleymaet R, De Bruyn H. Disparity in embrasure fill and papilla height between tooth- and implant-borne fixed restorations in the anterior maxilla: A cross-sectional study J Clin Periodontol. 2013;40:728–33 Cited Here 51. Gu YX, Shi JY, Zhuang LF, Qiao SC, Xu YY, Lai HC. Esthetic outcome and alterations of soft tissue around single implant crowns: A 2-year prospective study Clin Oral Implants Res. 2015;26:909–14 Cited Here 52.